IVF with Low AMH in Ahmedabad — Realistic, Individualised Fertility Care

A low AMH result can feel like a verdict. It is not. AMH (anti-Müllerian hormone) is a useful marker of how many eggs remain — your ovarian reserve — but it says very little about the quality of those eggs, and it does not, on its own, decide whether you can conceive. This page explains what a low AMH really means, how fertility care is planned around it at Balaji Horizon Women’s Hospital, Science City Road, Ahmedabad, and why an honest, individualised plan matters far more than the number itself.

What AMH measures — and what it does not

AMH is produced by the small, resting follicles in the ovaries, so it gives a reasonable estimate of the quantity of eggs still available. It is most useful for one practical purpose: predicting how the ovaries are likely to respond to stimulation during IVF, which helps tailor the medication dose. What AMH does not tell you is just as important:

• It does not measure egg quality — and quality, which is driven mainly by age, matters more for a healthy pregnancy.
• It does not reliably predict natural conception in a given month.
• A single value can vary between laboratories and assays, so it should be read alongside an antral follicle count (AFC) on ultrasound and, where relevant, FSH.

In short: a low AMH means there may be fewer eggs to work with, not that the door is closed.

What a low AMH does and does not mean for you

Two women with the same low AMH can have very different outlooks because age is the stronger predictor of egg quality and live birth. A younger woman with a low AMH often still has good-quality eggs; the challenge is mainly the number retrieved per cycle. An older woman faces both fewer eggs and a higher proportion that are not chromosomally normal. This is why we never counsel from the AMH number alone — your age, AFC, medical history and fertility goals together shape what is realistic.

Why AMH can be low

• Age — the commonest reason; reserve declines naturally over time.
• Diminished ovarian reserve at a younger-than-expected age (sometimes unexplained).
• Previous ovarian surgery — particularly repeated surgery for endometriosis or ovarian cysts, which can remove healthy ovarian tissue. This is a key reason we favour fertility-sparing, conservative surgery and avoid unnecessary repeat operations.
• Endometriosis itself, genetic factors, or prior chemotherapy/radiotherapy.

How we assess ovarian reserve at Balaji Horizon

• AMH blood test — interpreted with the assay in mind, never in isolation.
• Antral follicle count (AFC) on high-resolution transvaginal ultrasound — a direct, real-time count of resting follicles.
• FSH and oestradiol where indicated, plus a full history including any previous ovarian surgery.

Reserve testing guides the plan; it is not a pass/fail score.

Treatment when AMH is low — an honest, individualised approach

The guiding principle is to make the most of the eggs you have, not to chase the number. Internationally recognised frameworks for low-prognosis patients (such as the POSEIDON criteria) and ovarian-stimulation guidance from ESHRE inform how we plan care.

1. Individualised stimulation

For women with reduced reserve, a thoughtfully chosen protocol matters more than simply using the highest dose. Very high doses do not manufacture eggs that are not there and can add cost and side-effects without improving outcomes. The aim is the right protocol for your ovaries.

2. Making each cycle count

Strategies may include freezing eggs or embryos over more than one cycle to accumulate a reasonable number before transfer, and prioritising the timing of treatment — because with a declining reserve, time is the one variable we cannot recover.

3. Realistic, transparent counselling

We will give you an honest picture, including when the chance with your own eggs is limited and what the ethical alternatives (such as donor eggs) involve, so you can make an informed decision. We do not quote guaranteed success figures — anyone who does is not being straight with you.

4. Protecting the reserve you have

If you also have endometriosis or ovarian cysts, we weigh any surgery carefully against its effect on the ovary, to avoid further depleting reserve. Read more about IVF for endometriosis patients.

Low AMH — our approach & key answers

Last clinically reviewed by Dr. Priyadatt Patel on 5 June 2026.

How low is “low”? Making sense of your AMH and AFC numbers

One of the hardest things about a low AMH result is that the number arrives with no context. It helps to know the bands clinicians actually use — and, just as importantly, what they can and cannot tell you. AMH is reported in ng/mL in most Indian laboratories (multiply by about 7.14 for pmol/L), and a single value should always be read alongside an antral follicle count (AFC) on ultrasound and your age, never on its own. Results also vary between assays and laboratories, so a borderline figure is worth repeating before any conclusion is drawn.

These bands are guides, not verdicts. The internationally used “poor ovarian response” thresholds (an AFC under about 5–7, or AMH under roughly 0.5–1.1 ng/mL) come from the ESHRE Bologna consensus and were designed to predict how the ovaries respond to IVF stimulation — not to predict whether you can have a baby. Two women with an identical “low” AMH can have very different outlooks, because age, not the number, is the stronger driver of egg quality.

What a low AMH does — and does not — predict (the evidence)

This is where careful, evidence-based counselling matters most, because a great deal of fear is built on a misreading of what AMH measures.

• AMH predicts egg quantity, not egg quality. It estimates how many eggs are likely to be retrieved in an IVF cycle and helps choose the medication dose. Quality — the chance an egg is chromosomally normal — is driven mainly by age.
• A low AMH does not, by itself, mean you cannot conceive naturally. In a prospective study of women aged 30–44 with no history of infertility, those with low AMH (under 0.7 ng/mL) were not significantly less likely to conceive within 6 or 12 months than women with normal levels. AMH and FSH did not usefully predict natural fertility in this group.
• It is a planning tool, not a deadline. A low result is a reason to seek timely advice and not to lose months — but it is not a closed door.

The honest summary: a low AMH usually means there may be fewer eggs to work with per cycle, which changes how we plan treatment — not a single, fixed answer about your chance of a baby.

The POSEIDON framework: a smarter way to think about “low prognosis”

The older view divided patients crudely into “normal” or “poor” responders. That label lumped very different women together and offered no plan. The POSEIDON classification (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number) replaced it with something more useful: four groups defined by age (a proxy for egg quality), ovarian-reserve markers (AMH below ~1.2 ng/mL or AFC below ~5), and — where a previous cycle exists — how the ovaries actually responded. Around half of all IVF patients fit one of these groups, so this is the rule, not the exception.

Why this matters to you: a 32-year-old with a low AMH (Group 3) usually has good-quality eggs and mainly faces the challenge of number per cycle — a very different conversation from a 41-year-old with the same AMH (Group 4), who faces both fewer eggs and a higher proportion that are not chromosomally normal. Same number, different plan.

Treatment “add-ons”: what the evidence actually shows

Low AMH attracts heavily marketed supplements and add-ons — DHEA, growth hormone, testosterone, CoQ10 and others. We think you deserve a straight answer rather than a sales pitch. The ESHRE ovarian-stimulation guideline reviewed these and does not recommend them for routinely improving IVF outcomes, because the evidence is insufficient. In its most recent update, ESHRE noted that none of its evidence-based recommendations in this field rest on high-quality evidence — a reminder to be cautious of anyone who promises certainty, or a supplement that “raises” your reserve.

What genuinely helps is less glamorous and more honest:

• The right protocol, not the highest dose. Very high doses cannot manufacture eggs that are not there; they mainly add cost and side-effects. A GnRH-antagonist protocol is generally preferred for its comparable results and better safety.
• Making each cycle count. Where appropriate, eggs or embryos can be collected over more than one cycle to accumulate a reasonable number before transfer.
• Respecting time. With a declining reserve, time is the one variable we cannot recover — so we plan promptly rather than delaying for unproven treatments.
• Protecting what you have. If endometriosis or an ovarian cyst is also present, we weigh any surgery carefully against its effect on the ovary, because repeated surgery can lower reserve further.

Common questions about low AMH

Read this alongside our honest guide to what IVF success rates really mean (where age is the dominant factor) and our overview of fertility preservation and egg freezing — both directly relevant when reserve is reduced and time matters.

Prepared by the clinical team at Balaji Horizon Women’s Hospital and reviewed by Dr. Priyadatt Patel, MBBS, MS (Obstetrics & Gynaecology) — specialist in IVF & reproductive medicine, endometriosis and advanced laparoscopic surgery. Content aligned with the ESHRE ovarian-stimulation guideline (2025 update) and the POSEIDON criteria. Educational only; it does not replace an individual consultation. Last reviewed 17 June 2026.